On Tuesday, Pfizer Inc. (PFE.N) Chief Executive Officer Albert Bourla announced that the firm has submitted a request to the US Food and Drug Administration for approval of its COVID-19 booster dosages for use in 16 and 17-year-olds.
All individuals 18 and older are now eligible for a booster dosage of Pfizer and BioNTech's vaccine, which must be administered at least six months after the second injection, according to US authorities.
If approved, Pfizer's booster vaccine will be the first to be approved for use in children under the age of 18.
According to the Wall Street Journal, the FDA might approve Pfizer's booster dosages for 16- and 17-year-olds as early as next week.
The US government and health officials are pressing for more immunizations to stop the spread of the extremely contagious Omicron coronavirus strain, which was initially discovered in southern Africa.
/Next-COVID-Strain.jpeg "People walk past an advertisement warning about COVID-19 in Manchester, England, on Saturday. (Photo: Reuters)")
/COVID-Global-Emergency-WHO.webp "Millions of cases are being reported each week, but surveillance has declined, making it difficult to get a full overview of the situation and how the virus is mutating. (Photo: Reuters)")
/WHO-COVID-END.jpg "Tedros Adhanom Ghebreyesus, Director General of WHO, speaks with Charles Michel, EU Council President, during the G7 leaders summit at Castle Elmau in Kruen, Germany, on Monday, June 27, 2022. (Michael Kappeler/Pool via AP)")
/Monkeypox-Outbreak-Health-Emergency.jpg "Daniel Rofin, 41, receives a vaccine against Monkeypox from a health professional in medical center in Barcelona. (Photo: AP)")
/South-American-Monkeypox-Cases.webp "The monkeypox virus has been found in 78 countries since early May according to the WHO [File: Rick Bowmer/AP Photo]")
/Global-Health-Emergency-Monkeypox.jpg "Test tubes labelled \"Monkeypox virus positive\" are seen in this illustration taken May 22, 2022. (Photo: Reuters/Dado Ruvic)")
